Corcept Therapeutics Incorporated (CORT) Fair Value & Analysis
Healthcare · US · Market cap $7.6B
Corcept Therapeutics Incorporated
CORT · US
Fair value as of: Jun 24, 2026
From 26 valuation models · updated 9 days ago
Fair value updated Jun 24, 2026 — revised from $25.68 to $15.78 (−38.6%) since Jun 23, 2026. Share price +26.7% over the past month.
Price vs Fair Value (12 months)
12‑month range $28.46 – $79.95 · fair‑value band $11.84 – $30.22 · the $79.85 price screens above the $15.78 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Corcept Therapeutics Incorporated (CORT) currently trades at $79.85, while our model-based Fair Value estimate is $15.78 — implying the stock looks roughly 80.2% overvalued today. We read business quality at 67/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Corcept Therapeutics Incorporated generated revenue of $769M at a net margin of 6.2%. Revenue grew 4.9% year over year. It earns a return on equity of 7.2%. The balance sheet holds a net cash position of $114M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Corcept Therapeutics Incorporated reported revenue of $761M in FY2025 versus $366M in FY2021, a compound +20.1%/yr. Reported net income was $99.7M in FY2025, compounding −3.0%/yr from FY2021.
Is CORT fairly valued? → Check now
Recent news
- 3 High-Flying Stocks We Steer Clear Of
- Alger Russell Innovation Index Updates for Second Quarter 2026
- Branded Pharmaceuticals Stocks Q1 Teardown: Supernus Pharmaceuticals (NASDAQ:SUPN) Vs The Rest
- 3 Unpopular Stocks We Steer Clear Of
External third-party headlines (Yahoo Finance, Reuters and others) — not an editorial selection, not financial advice.
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$574.00 | R$357.63 | -38% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €247.60 | €180.06 | -27% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $286.41 | $106.81 | -63% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Corcept Therapeutics Incorporated (CORT) undervalued?
What is the fair value of CORT?
What is the quality score of CORT?
What is the revenue of Corcept Therapeutics Incorporated (CORT)?
What is the net profit margin of CORT?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.